Medical AI Investors Are Scrambling to Recruit PhDs in Hong Kong

In the summer of 2026, medical AI projects at Hong Kong universities were collectively “blocked” on campus by capital.

Brainsmart Technology, an invasive brain-computer interface (BCI) team led by Professor Chen Guoliang of the University of Hong Kong, completed an angel financing round exceeding USD 10 million this year. The round was led by Bayland Capital, with participation from BlueRun Ventures. The company’s Hong Kong team leverages the Advanced Biomedical Instrumentation Centre (ABIC), jointly established by the University of Hong Kong and Harvard University, to develop electrode devices and AI decoding algorithms. Meanwhile, its Shenzhen team is responsible for engineering and Good Manufacturing Practice (GMP) production. The production line, located in the Hetao Shenzhen-Hong Kong Cooperation Zone, has already commenced construction.

AilsynBio, based at the Hong Kong Science Park, has become one of the first two companies invested in by the "Gobi–HKU Fund." Its founder, Yang Guanya, is a graduate of the Department of Chemistry at the University of Hong Kong and studied under renowned inorganic chemist Academician Chi-Ming Che. Less than a month after securing its seed funding round, AilsynBio signed a collaboration agreement with Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group. The two parties will leverage AilsynBio's AI-driven drug discovery platform to accelerate biomedical research and development.

Psyrene Technology, a startup incubated at the PolyU Shenzhen Entrepreneurship Center and led by Hong Kong Polytechnic University alumnus Liu Haowen, has secured millions in seed funding. The company combines smart hardware with large AI models to provide home-based management solutions for chronic diseases and mental health disorders.

Snatching up AI PhDs in Hong Kong has become the latest craze among mainland Chinese funds and investors. Flights heading south to Hong Kong have lately been packed with investors, who are not only jostling for space but also gearing up for action. But on this emerging hotbed of entrepreneurship, can medical AI truly blossom?

The Starting Point of the Wave Was Not in Healthcare.

In the first half of 2026, a set of financing data put entrepreneurs with backgrounds from Hong Kong universities in the spotlight. According to statistics, in the first half of 2026, 19 companies founded by entrepreneurs with ties to the Hong Kong University of Science and Technology (HKUST) completed 25 rounds of financing, with an estimated total exceeding RMB 8.4 billion. Meanwhile, 15 companies founded by entrepreneurs affiliated with the Chinese University of Hong Kong (CUHK) secured financing, with an estimated cumulative amount surpassing RMB 1.5 billion. Notably, investments in the field of embodied intelligence accounted for more than 70% of the total financing amount.

Archon Robotics is the most high-profile case of 2026. In April 2026, the company, less than a month old, announced the completion of its seed funding round, amounting to several hundred million yuan. The investor lineup included six top-tier venture capital firms: ZhenFund, Gaorong Ventures, IDG Capital, 5Y Capital, Gobi Partners, and MiraclePlus. The founder, Li Hongyang, is an Assistant Professor and Associate Dean of the Faculty of Computing and Data Science at the University of Hong Kong. During the same period, TranscEngram completed an angel round worth several hundred million yuan. Its investors included Sino Biopharmaceutical Limited, Pudong Venture Capital, Zhangjiang Hi-Tech Investment, and Cloud Bay Capital. The founder, Ma Yi, is the Founding Dean of the Faculty of Computing and Data Science at the University of Hong Kong, a recipient of the Marr Prize in computer vision, and a triple Fellow of IEEE, ACM, and SIAM. His research focuses on the unified "cerebrum + cerebellum" architecture for embodied intelligence.

Furthermore, SPARO completed four rounds of financing within less than a year of its establishment, raising hundreds of millions of yuan. Investors included Alibaba, GLP, and Hony Capital. The founder, Zhang Fu, is an associate professor in the Department of Mechanical Engineering at the University of Hong Kong and a former scientist at DJI. Ola Dimensions, founded in 2025, secured two rounds of financing totaling hundreds of millions of yuan within 60 days, with Ant Group and Didi Chuxing as investors. Its founder, Zhou Shunbo, holds a PhD in Robotics from the Chinese University of Hong Kong, was a Huawei “Genius Youth” awardee, and served as the first employee (“Employee No. 1”) in Huawei’s embodied intelligence division. GenRobot, which also received joint lead investment from Ant Group and Didi Chuxing, has a founding team with backgrounds from the Chinese University of Hong Kong.

“Teams from Hong Kong universities often naturally possess stronger commercial awareness and a global perspective. They have solid academic training, strong English proficiency, the ability to connect with international academic networks, and exposure to the working methods of top-tier laboratories. This gives them superior inherent conditions for entrepreneurship,” an investor explained to VCBeat.

In Hong Kong, although medical AI startups originating from universities have generated far less buzz than embodied intelligence, their rapid rise cannot be ignored. “Hong Kong has never been the preferred destination for healthcare entrepreneurs,” the aforementioned investor told VCBeat. “Due to limited medical resources and less developed supporting industries compared to some regions in mainland China, its appeal is limited for increasingly competitive healthcare ventures.” However, this landscape is undergoing profound changes this year.

In addition to Brainsmart Technology, AilsynBio, and Psyrene Technology mentioned at the beginning of the article, Endong Medicine, incubated by the Hong Kong Innovation Academy of the Chinese Academy of Sciences, completed its angel round of financing in February 2026. In this place where almost everything is ready, the explosion of the medical AI wave only lacks a final catalyst.

In this process, the Hong Kong University of Science and Technology, the Chinese University of Hong Kong, and the University of Hong Kong, as the three universities with the largest number of technology commercialization projects, began to systematically improve the ecosystem for healthcare entrepreneurship.

For instance, the Hong Kong University of Science and Technology (HKUST) has established a comprehensive incubation pipeline: IncuTech provides early-stage validation, HKSTP STEP offers growth resources, and TSSSU supplies funding, ensuring seamless interfaces at every stage from laboratory to capital. In contrast, the University of Hong Kong (HKU) directly connects with capital markets: its Technology Transfer Office (TTO) screens projects, while the HKUMed Xelerate Challenge fosters an innovative ecosystem. In March 2026, HKU jointly established the FutureTech Stars Fund with CASSTAR, with an initial size of HK$150 million, directly introducing top-tier mainland Chinese capital into the HKU campus.

Another example is the deliberate effort by The Hong Kong Polytechnic University and City University of Hong Kong to establish engineering-oriented commercialization pathways for “med-tech integration.” Notably, the trustworthy AI framework TRUEAAM, developed by Professor Zhang Xiaoge’s team, was published in Nature Biomedical Engineering, while the AI system for fundus angiography developed by Professor He Mingguang’s team achieved a sensitivity of 96.2%. Both achievements have been validated by international awards, successfully bridging the critical gap from academic publication to engineering commercialization. Furthermore, InnoHK, as the HKSAR Government’s most pivotal policy lever, has leveraged its two clusters—Health@InnoHK and AIR@InnoHK—to foster collaborations between Harvard University, MIT, Stanford University, and local universities. This initiative has introduced international standards and industrial resources, incubating Brainsmart Technology and supporting MicroNeuro.

When viewed over a longer timeframe, it becomes evident that entrepreneurs from Hong Kong universities have never been newcomers to China’s healthcare innovation and entrepreneurship landscape. Startup teams hailing from the eight established Hong Kong universities have launched influential flagship projects in cutting-edge sectors such as AI-driven drug discovery, surgical robotics, and precision diagnostics.

In 2017, Dr. Brain was established in Shenzhen. Its founder, Wang Silun, pursued his studies and worked at the University of Hong Kong and Johns Hopkins University in the United States, with his doctoral research focusing on biomedical imaging. At the outset of his entrepreneurial venture, he chose not to return to Hong Kong but instead directly built a core R&D team in Shenzhen.

Dr. Brain’s strategy centers on AI-driven precision diagnosis and drug screening, with its core technology platform built around medical imaging and biomarker modeling. In its first year, Dr. Brain secured angel-round funding from a domestic RMB-denominated fund, which supported the expansion of its core team and the development of product prototypes. Since then, the company has maintained a steady fundraising pace: Series A introduced strategic industrial capital, while Series B saw participation from leading institutional investors, gradually establishing a commercialization pathway in AI-based imaging diagnosis and biomarker modeling.

Currently, Dr. Brain’s products have been adopted by dozens of medical institutions, establishing stable hospital access channels in the niche segment of AI-assisted diagnosis. Notably, Wang Silun has maintained a consistent practice of academic collaboration with Hong Kong universities, regularly returning to the University of Hong Kong’s laboratories to participate in cutting-edge research projects. Meanwhile, Dr. Brain has established a small clinical collaboration team in Hong Kong to liaise with imaging data resources from hospitals affiliated with the University of Hong Kong system, leveraging these data for algorithm training and clinical validation.

In 2019, Professor Ou Guowei of The Chinese University of Hong Kong founded Cornerstone Robotics. Prior to this, Professor Ou had worked for nearly a decade at Intuitive Surgical, the parent company of the da Vinci surgical robot, where he led the development of the Da Vinci Single-Site and Da Vinci Ion systems. In 2016, Professor Ou returned to The Chinese University of Hong Kong as a professor in the Department of Mechanical and Automation Engineering and as the Director of the Centre for Medical Robotics Innovative Technologies.

Coincidentally, Ou Guowei also established the headquarters of Cornerstone Robotics in Shenzhen. In November 2020, Cornerstone Robotics completed its Series A financing round, with Qiming Venture Partners leading the investment. The company secured multiple rounds of funding in 2021, 2023, and 2025, attracting top-tier investment institutions and authoritative funds such as Lilly Asia Ventures, Meituan Longzhu, Lenovo Capital, Hong Kong Investment Corporation, and global sovereign wealth funds. Qiming Venture Partners continued to follow up with subsequent investments. In June 2023, Cornerstone Robotics closed an RMB 800 million Series B+ round, marking its first entry into this financing stage, with BridgeOne Technology Investment and others participating as co-investors. By the end of 2025, Cornerstone Robotics had raised a cumulative total of over RMB 3 billion.

Cornerstone Robotics’s flagship product, the Sentire laparoscopic surgical robot, is positioned as a competitor to the da Vinci system. It obtained the Class III registration certificate from China’s National Medical Products Administration (NMPA) in September 2024 and simultaneously launched clinical commercialization in specialties such as urology and general surgery. Cornerstone Robotics’s clinical team shares surgical data and clinical feedback with the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) to continuously optimize the robot’s control algorithms. Meanwhile, PhD candidates from CUHK’s Surgical Robotics Research Center complete engineering training at Cornerstone Robotics’s Shenzhen factory, fostering two-way talent exchange. Ou Guowei once stated that university-based R&D accounts for only 5% of the entire development process, while the remaining 95% is learned during industrialization. In his view, providing students from Hong Kong universities with opportunities for hands-on engineering training is crucial.

In 2018, Professor Mengsu Yang, Senior Vice President of City University of Hong Kong and Fellow of the National Academy of Inventors (USA), registered and established Cellomics in the Hong Kong Science Park. Since 2000, Professor Yang has been conducting research on liquid biopsy for cancer, systematically building a technological platform ranging from circulating tumor cells (CTCs) to circulating tumor DNA (ctDNA), thereby establishing the core technical barriers for Jingzhun Medicine.

In 2021, Cellomics completed its Series A financing round, led by Proxima Ventures, with participation from Hillhouse Capital and Alibaba Entrepreneurs Fund. Subsequently, the company completed its Pre-Series B and Series B financing rounds in 2022 and 2024, respectively, introducing Tiger Jade Capital, industrial capital, and alumni capital affiliated with City University of Hong Kong. Leveraging detection technologies for circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), Cellomics facilitates early cancer screening and companion diagnostics in clinical practice.

Since founding the company, Yang Mengsu has continued to teach and supervise doctoral students at City University of Hong Kong, with his research team consistently transferring cutting-edge technologies to the company. Meanwhile, the company has established clinical validation laboratories in Hong Kong and Shenzhen, respectively, and launched collaborative clinical projects on liquid biopsy with multiple public hospitals in Hong Kong.

Interestingly, in the aforementioned startup stories, besides hailing from Hong Kong universities, the founding teams invariably established their operational headquarters in mainland China. In addition to the industrial ecosystem factors mentioned earlier, the low risk tolerance of local Hong Kong venture capital firms toward hard-tech projects is another reason why Hong Kong PhD graduates have traditionally chosen to launch startups outside the city. “Although Hong Kong is a major global financial center, it is difficult to find investors willing to take risks and provide long-term support during the early stages of entrepreneurship,” said an industry practitioner.

In other words, for previous PhD holders in Hong Kong, the mechanism to secure the first round of external funding for starting a business in Hong Kong was lacking.

Since 2026, the most notable change has been that capital has begun to proactively flow into Hong Kong, rather than waiting for teams from Hong Kong universities to emerge.

On one hand, the HKSAR Government is proactively stepping up its efforts. Hong Kong Investment Corporation (HKIC), the entity under the HKSAR Government that manages multiple industrial investment funds, has begun to directly participate as a cornerstone investor in funds. This signifies that the HKSAR Government is no longer merely providing policy facilitation but is actively engaging with substantial capital to help mainland Chinese investors reduce their risk exposure when betting on Hong Kong. Hong Kong’s universities are also taking concurrent action. In 2026, the HKSAR Government announced an injection of HK$1.5 billion into the innovation and technology sector to optimize the “Industry-Academia-Research 1+ Scheme,” subsidizing the commercialization of scientific research achievements from local universities. During the same period, the Hong Kong University of Science and Technology (HKUST) jointly established a biotechnology-focused fund with Shanghai Industrial Holdings (Group) Company and other Shanghai state-owned capital entities. Furthermore, established firms long-rooted in Greater China, such as Gobi Partners, have directly assumed the role of fund managers, managing innovation and technology funds co-branded with Hong Kong universities.

On the other hand, mainland capital has responded more quickly than anticipated. RMB-denominated funds with keen market instincts have been entering Hong Kong in bulk, with state-backed institutions such as Shenzhen Capital Group, Pudong Venture Capital, and China Merchants Venture Capital frequently appearing on the investor lists of startup projects from Hong Kong universities. Meanwhile, industrial capital is following suit; investors with clear industrial logic, such as Ant Group, Didi Chuxing, Meituan Longzhu, and Lilly Asia Ventures, have begun to incorporate projects from Hong Kong universities into their respective industrial layouts.

The driving forces behind this are not difficult to understand.

First is the valuation gap. The valuation systems for early-stage projects at Hong Kong universities have not yet been fully priced in by the fervor of the mainland Chinese market, allowing mainland capital to acquire equity stakes at a lower cost for comparable levels of technological sophistication. Second is the endorsement effect of HK Investment Company. The injection of funds from the SAR government serves as a due diligence filter for investment institutions, providing a trusted third-party assessment of project quality and academic merit, thereby significantly shortening the decision-making cycle for investors. Third, Shenzhen-Hong Kong collaboration reduces commercialization risks. With R&D in Hong Kong and manufacturing in Shenzhen, the two cities are close enough for same-day round trips, allowing each to maximize its respective advantages. This division of labor, already validated by DJI and Huawei, is now being replicated in the medical AI sector.

As a result, PhD candidates at Hong Kong universities no longer need to leave the city to secure access to mainland Chinese capital. In a sense, Hong Kong’s higher education institutions are evolving into a significant technology procurement market. The underlying rationale for mainland investors seeking projects in Hong Kong university laboratories is that scientists there have received Western academic training, are fluent in English, and can align with international standards, all while commanding lower labor costs than those in Silicon Valley. Once a project successfully passes technical validation, mainland investors typically relocate the company to Shenzhen or Suzhou for commercialization.

At its core, this represents an extension of the "R&D in Hong Kong, manufacturing in the mainland" division-of-labor model into the medical AI sector, with this supply chain now becoming shorter and more efficient.